Arrhythmias and Sudden Cardiac Death

Research Focus:
Michigan Resuscitation Innovation and Science Enterprise (M-RISE)

Center Director:
Robert Neumar, MD, PhD, FAHA

Training Director:
David Pinsky, MD

 

Principal Investigators

• Thomas Sanderson, PhD
  Early Neuroprotective Therapies for Out-of-Hospital Cardiac Arrest


• Robert Silbergleit, MD, FAHA
  Bystander and First Responders Clinical Trials for Early Neuroprotective Therapies in Out-of-Hospital Cardiac Arrest


• Brahmajee Nallamothu, MD, MPH, FAHA
  Optimizing Bystander and First Responder Time to Treatment in Out-of-Hospital Cardiac Arrest

Research Focus:
Northwestern Sudden Cardiac Death Collaboration

Center Director:
Elizabeth McNally, MD, PhD

Training Director:
Richi Arora, MD, FAHA

Principal Investigators:

• Alfred “Al” George, MD
  Correlating SCD Risk with Cell Autonomous Susceptibility


• Elizabeth McNally, MD, PhD
  Genomics of Arrhythmias and Sudden Death


• Laura Rasmussen-Torvik, PhD, MPH, FAHA
  Integration of Genomics into Clinical Care for SCD

 

Research Focus:
Genomic and Precision Medicine Approaches to Evaluate Sex- Specific SCA Risk and Resuscitation Outcomes

Center Director:
Nona Sotoodehnia, MD, MPHD

Training Director:
Francis Kim, MD, FACC, FACP
Michael Sayre, MD, FAHA

Principal Investigators:

• Ilan Goldenberg, MD
  Sex-Specific Risk for QTc Prolongation and Arrhythmic Events in Congenital and Drug Induced LQTS


• Thomas Rea, MD, MPH
  Precision Medicine Resuscitation: Novel Strategy for Real- Time Rhythm Assessment during CPR


• Dan Arking, PhD
  Genomics of Sudden Cardiac Arrest Risk among Men and Women

Research Focus:
Targeting Intracellular Calcium Leak for Ventricular Arrhythmia Prevention in Structural Heart Disease

Center Director:
Bjorn Knollmann, MD, PhD

Training Director:
Dan Roden, MD, FAHA

Principal Investigators:

• Bjorn Knollmann, MD, PhD
  The Mechanistic Role of RyR2 Hyperactivity for Ventricular Arrhythmia in Animal Models


• Igor Efimov, PhD
  The Mechanistic Role of RyR2 Hyperactivity for Ventricular Arrhythmia in the Ex Vivo Human Heart


• William Stevenson, MD
  A Clinical Trial of RyR2 Inhibition to Prevent Ventricular Arrhythmias